<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2856">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04939792</url>
  </required_header>
  <id_info>
    <org_study_id>HRP-503</org_study_id>
    <nct_id>NCT04939792</nct_id>
  </id_info>
  <brief_title>Optimization of Blood Levels of 25(OH)-Vitamin D in African Americans</brief_title>
  <official_title>Optimization of Blood Levels of 25(OH)-Vitamin D in African Americans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Louisiana State University Health Sciences Center Shreveport</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Louisiana State University Health Sciences Center Shreveport</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Two-thirds of the US population, particularly African Americans (AA), is at risk for&#xD;
      inadequate or deficient 25-hydroxy-vitamin D (25(OH)VD). Epidemiological studies demonstrate&#xD;
      an association between better health outcomes and higher blood levels of 25(OH)VD .&#xD;
      Randomized controlled clinical trials have shown that, while supraphysiological high doses of&#xD;
      VD are needed to achieve adequate blood levels of 25(OH)VD, not all subjects respond to them.&#xD;
      Recent studies have also questioned the therapeutic effects of high-dose VD supplementation.&#xD;
      Severe VD deficiency has been associated independently with the future risk of mild cognitive&#xD;
      impairment (MCI) and dementia. A reduction in GSH and an increase in the oxidative stress&#xD;
      levels of serum, erythrocytes, and circulating lymphocytes has been observed in MCI and&#xD;
      Alzheimer disease, findings similar to those in VD deficient persons. Scholarly reviews&#xD;
      conclude that excess oxidative stress is one of the major risk factors for AD and support a&#xD;
      potential therapeutic role for L-cysteine (LC, a GSH precursor) and vitamin D (VD)&#xD;
      supplementation in the treatment of Alzheimer disease symptoms. This application presents the&#xD;
      investigators' design for a randomized, double-blind, placebo-controlled clinical trial to&#xD;
      test the hypothesis that supplementation with VD in combination with L-cysteine (LC) is more&#xD;
      successful at optimizing the statuses of 25(OH)VD [biological signatures] and simultaneously&#xD;
      decreasing TNF-α, IR [functional or clinical outcomes], and oxidative stress, suggesting a&#xD;
      better therapeutic approach compared with supplementation with VD alone in AA subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 6, 2020</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>25-hydroxy-vitamin D</measure>
    <time_frame>6 months</time_frame>
    <description>Change in blood levels of 25(OH)VD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TNF-α</measure>
    <time_frame>6 months</time_frame>
    <description>Whether any increase in vitamin D beneficially decreases insulin resistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA-IR</measure>
    <time_frame>6 months</time_frame>
    <description>Whether any decrease in TNF-a beneficially decreases insulin resistance</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Initially, all of the study subjects will be provided placebo supplementation as a placebo run-in period for one month before randomization. The placebo run-in period is meant to stabilize subjects in the study and will prevent any effect due solely to inclusion in the study. Placebo and supplement capsules will be similar in appearance, taste, texture, and smell, and will be provided by the pharmacist, who will have the codes for which subjects are assigned to which supplement or placebo.&#xD;
During testing, the placebo group will take two placebo capsules a day in the morning. Supplements will be taken daily with food at breakfast for 6 months, while participants continue to carry on a normal lifestyle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L-Cysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LC group will receive two capsules of LC daily. Supplements will be taken daily with food at breakfast for 6 months, while participants continue to carry on a normal lifestyle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VD group will take two capsules and each capsule will contain 1000 IU VD daily. Supplements will be taken daily with food at breakfast for 6 months, while participants continue to carry on a normal lifestyle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D3 and L-Cysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VD+LC group will take daily two capsule containing 1000 IU+500 mg LC. Supplements will be taken daily with food at breakfast for 6 months, while participants continue to carry on a normal lifestyle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Capsules ingested orally</description>
    <arm_group_label>Vitamin D3</arm_group_label>
    <other_name>cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule ingested orally</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>starch</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D + L-cysteine</intervention_name>
    <description>Capsule ingested orally</description>
    <arm_group_label>Vitamin D3 and L-Cysteine</arm_group_label>
    <other_name>combination of vitamin D and L-cysteine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-cysteine</intervention_name>
    <description>Capsule ingested orally</description>
    <arm_group_label>L-Cysteine</arm_group_label>
    <other_name>amino acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  African American volunteers only&#xD;
&#xD;
          -  Participants between the ages of 18 and 65&#xD;
&#xD;
          -  Must be In good general health&#xD;
&#xD;
          -  Women with negative pregnancy tests&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with Diabetes, Heart disease, Sickle Cell disease, or Epilepsy&#xD;
&#xD;
          -  Subjects with serum positive pregnancy test or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sushil K Jain, Ph.D</last_name>
    <phone>318-675-6086</phone>
    <email>sushil.jain@lsuhs.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alonzo L Zachary</last_name>
    <phone>318-675-6086</phone>
    <email>alz001@lsuhs.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Louisiana State University Health Shreveport</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sushil K Jain, PhD</last_name>
      <phone>318-675-6086</phone>
      <email>sushil.jain@lsuhs.edu</email>
    </contact>
    <investigator>
      <last_name>Sushil K Jain, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2022</verification_date>
  <study_first_submitted>June 8, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2021</study_first_posted>
  <last_update_submitted>September 2, 2022</last_update_submitted>
  <last_update_submitted_qc>September 2, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Louisiana State University Health Sciences Center Shreveport</investigator_affiliation>
    <investigator_full_name>Sushil Jain</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>African American;</keyword>
  <keyword>Vitamin D;</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Alzheimer's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After completion of the study</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>3 years</ipd_time_frame>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 6, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT04939792/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 7, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT04939792/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

